abiraterone has been researched along with Disease Models, Animal in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, AKY; Fu, WY; Gu, S; Huang, X; Ip, FCF; Ip, NY; Tong, EPS | 1 |
| Corey, E; Lam, HM; Nguyen, HM | 1 |
| Bowden, M; Christie, A; Huang, Y; Kantoff, PW; Lee, GS; Sweeney, CJ; Wang, X | 1 |
| Armstrong, CM; Evans, CP; Gao, AC; Liu, C; Lombard, A; Lou, W | 1 |
| Balk, S; Marck, BT; Matsumoto, AM; Montgomery, RB; Mostaghel, EA; Nelson, PS; Plymate, SR; Vessella, RL | 1 |
5 other study(ies) available for abiraterone and Disease Models, Animal
| Article | Year |
|---|---|
Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs.
Topics: Alzheimer Disease; Androstenes; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cyproheptadine; Disease Models, Animal; Diterpenes; Drug Evaluation, Preclinical; Hippocampus; Ligands; Mice; Mice, Transgenic; Molecular Docking Simulation; Neurons; Protein Binding; Protein Domains; Pyrimidines; Receptor, EphA4 | 2018 |
Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.
Topics: Androstenes; Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Heterografts; Humans; Male; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mice, Transgenic; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity.
Topics: Androstenes; Anilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Antagonism; Drug Resistance, Neoplasm; Humans; Male; Mice; Phosphorylation; Prostatic Neoplasms; Pyridines; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Receptors, Androgen; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Androstenes; Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Hydroxyprostaglandin Dehydrogenases; Male; Mice; Neoplasm Staging; Prostatic Neoplasms; Receptors, Androgen; Transcription, Genetic; Xenograft Model Antitumor Assays | 2017 |
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
Topics: Alternative Splicing; Androgens; Androstenes; Androstenols; Animals; Biosynthetic Pathways; Cell Proliferation; Dihydrotestosterone; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Xenograft Model Antitumor Assays | 2011 |